Education
About Us
Working with TipRanks
Follow Us
Ocumension Therapeutics (HK:1477)
:1477
RESEARCH TOOLSreports
1477 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$3.62 - HK$9.75
Previous CloseN/A
Volume1.11M
Average Volume (3M)7.37M
Market Cap
HK$7.41B
Enterprise ValueHK$4.34B
Total Cash (Recent Filing)HK$769.21M
Total Debt (Recent Filing)¥25.78M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 13, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding834,780,500
10 Day Avg. Volume9,149,274
30 Day Avg. Volume7,365,762
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.99
Price to Sales (P/S)0.00
P/FCF Ratio-10.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.29Price Target Upside-25.99% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Ocumension Therapeutics News
PremiumCompany Announcements
Ocumension’s OT-703 Approved for Study in Hainan
PremiumCompany Announcements
Ocumension Therapeutics Announces 2025 Annual General Meeting
PremiumCompany Announcements
Ocumension Therapeutics Proposes Amendments to Optimize Operations
PremiumCompany Announcements
Ocumension Therapeutics Reports Significant Revenue Growth in 2024
PremiumCompany Announcements
Ocumension Therapeutics Announces Board Composition and Strategic RolesOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.41%
Mutual Funds
― Other Institutional Investors
97.01% Public Companies and
Individual Investors
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$3.62 and its highest was HK$9.75 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$7.41B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 13, 2025 which is in 59 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 31, 2025. The company reported -HK$0.183 earnings per share for the quarter, beating the consensus estimate of -HK$0.194 by HK$0.011.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Overvalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 834,780,500 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.183 in its last earnings report, beating expectations of -HK$0.194. Following the earnings report the stock price went up 1.606%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
Ocumension Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$7.29 (-25.99% Downside)
HK$7.29 (-25.99% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.49%
12-Months-Change
Fundamentals
Return on Equity
-8.04%
Trailing 12-Months
Asset Growth
17.43%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―